Your search history is turned on.
Date: April 25, 2024 Jurisdictions: Alberta, British Columbia, Ontario
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility TORONTO and HAIFA, Israel, April 25, 2024 -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the Company or NurExone), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB Venture Marke...
Date: April 19, 2024 Jurisdictions: Alberta, British Columbia, Ontario
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine TORONTO and HAIFA, Israel, April 19, 2024 -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the Company or NurExone), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolution...
Date: April 2, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, OVADYA, Eran, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable ...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Date: April 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario
[1] NUREXONE BIOLOGIC INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 [2] NUREXONE BIOLOGIC INC. TABLE OF CONTENTS Page Ind...
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update TORONTO and HAIFA, Israel, April 02, 2024 -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the Company or NurExone), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quart...
Microsoft Word - Innocan - Q3 2021 - CFO Certificate(47307730.2) (002) NOTE TO READER In contrast to the certificate required for non-venture issuers under National Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and...
NurExone Biologic Inc Managements Discussion and Analysis For the year ended December 31, 2023 (Expressed in thousands of U.S. dollars) Dated April 2, 2024 NurExone Biologic Inc. Managements Discussion and Analysis For the year ended December 31, 2023, and 2022 [1] This Managements Discussion and Analysis (MD&A) relates to the opera...
Date: March 27, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise TORONTO and HAIFA, Israel, March 27, 2024 -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the Company or NurExone), is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a private placement of units that closed on June 15...